|
|
|
|
Bayer bDNA 340 Analyzer System
|
| Selected Ad |
| Category: |
Laboratory |
| Title: |
Bayer bDNA 340 Analyzer System |
| Ad
Number: |
2936 |
| Date Posted: |
1/3/2011 |
| Contact: |
Nery Rosado
200 Miller Place
Hicksville, NY 11801
|
| Telephone: |
516-622-3838
|
|
|
|
|
|
Description
Used) Bayer System 340 bDNA Analyzer.
Bayer System 340 bDNA Analyzer. Bayer 340 Automated bDNA System. This new automated system represents a significant advance in the quantification of viral load measurements. By automating previously labor intensive steps in assay processing, the system reduces labor requirements, improves assay performance, and increases laboratory efficiencies. With a throughput up to 168 samples per run, the Bayer 340 Automated bDNA System meets the needs of both high- and low-volume laboratories
"Sold as is"
Price: $2,100 plus shipping
Bayer Versant™ HCV RNA 3.0 Assay (bDNA)
Bayer Diagnostics
PO Box 2466, Berkeley, CA 94702-0466
FDA Approval Date: March 28, 2003
What is it? This laboratory test measures the amount of hepatitis C viral RNA in a patient’s blood. Viral RNA (ribonucleic acid) is genetic material from the hepatitis C virus. This test is used with the Bayer System 340 bDNA Analyzer.
How does it work? In a laboratory, a sample of a patient’s blood is put into a tiny special container in a Bayer System 340 bDNA Analyzer. The Analyzer adds a series of chemicals that react with genetic material from the hepatitis C virus to ultimately produce light. The Analyzer measures the light, which shows how much hepatitis C viral RNA there was in the patient’s blood.
When is it used? A doctor uses this test two or more times while treating a patient with antiviral therapy to see if the patient has not responded to the anti-viral treatment.
What will it accomplish? This test will tell the doctor and patient if antiviral treatment has failed to help cure the patient of hepatitis C infection.
When should it not be used? The assay should not be used to determine if a person is infected with hepatitis C virus. It should not be used to screen blood or blood products for transfusion. And, it should not be used to predict whether an antiviral treatment will be successful.
|
|
|
|
|
|
|